Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 8/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.42 |
| ▸ | TP53 | P04637 | 3/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 4/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL108962 | 0.85 | TSHR (0.53) | TSHRHPGDALDH1A1TP53HIF1A | |
| SCHEMBL28464042 | 0.84 | TSHR (0.58) | TSHRHPGDALDH1A1TP53HIF1A | |
| SCHEMBL236552 | 0.82 | TSHR (0.65) | TSHRHPGDALDH1A1TP53HIF1A | |
| SCHEMBL238023 | 0.81 | TSHR (0.53) | TSHRHPGDALDH1A1TP53HIF1A | |
| SCHEMBL28453703 | 0.81 | TSHR (0.44) | TSHRHPGDALDH1A1TP53HIF1A | |
| SCHEMBL2584600 | 0.79 | TSHR (0.47) | TSHRHPGDALDH1A1TP53HIF1A | |
| SCHEMBL551679 | 0.78 | HCAR2 (0.39) | ALDH1A1HCAR2NPSR1 | |
| SCHEMBL81412 | 0.78 | TSHR (0.59) | TSHRHPGDALDH1A1TP53HIF1A | |
| SCHEMBL5406660 | 0.77 | TSHR (0.44) | TSHRHPGDALDH1A1TP53HIF1A | |
| SCHEMBL110716 | 0.77 | TSHR (0.58) | TSHRHPGDALDH1A1TP53HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 196 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4035649-B1 | DENTAL ADHESIVE COMPOSITION | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2023-07-26 | — | — | EP | claimed |
| EP-4035649-A1 | DENTAL ADHESIVE COMPOSITION | 3M Innovative Properties Company (US) | 2022-08-03 | — | — | EP | claimed |
| EP-3310792-B1 | PROCESS FOR PREPARING AN ACRYLOYLOXYSILANE | DOW SILICONES CORP (US) | 2021-07-21 | — | — | EP | claimed |
| CN-109266079-A | A kind of ACS doping inorganic nano fungicidal paint and preparation method thereof | 湖南凯斯利新材料有限公司 | 2019-01-25 | — | — | CN | claimed |
| US-20010053813-A1 | Rubber compositions | JSR CORPORATION (JP) | 2001-12-20 | — | — | US | claimed |
| EP-4747320-A1 | THERMAL-AND UV-CURABLE (METH) ACRYLATE COMPOSITION | Henkel AG & Co. KGaA (DE) | 2026-05-27 | — | — | EP | disclosed |
| US-20260139157-A1 | THERMAL-AND-UV-CURABLE (METH)ACRYLATE COMPOSITION | HENKEL AG & CO KGAA (DE) | 2026-05-21 | — | — | US | disclosed |
| US-20260028440-A1 | Curable Composition for Producing Transparent Orthodontic Attachments | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2026-01-29 | — | — | US | disclosed |
| US-12319815-B2 | Resin composition, method for producing same, and multi-liquid curable resin composition | KANEKA CORPORATION (JP) | 2025-06-03 | — | — | US | disclosed |
| US-12312494-B2 | Resin composition, method for producing same, and multi-liquid curable resin composition | KANEKA CORPORATION (JP) | 2025-05-27 | — | — | US | disclosed |
| CN-114829430-B | Curable composition comprising a multistage polymer | 阿科玛法国公司 | 2025-04-22 | — | — | CN | disclosed |
| CN-119584936-A | Curable composition for producing transparent orthodontic accessories | 舒万诺知识产权公司 | 2025-03-07 | — | — | CN | disclosed |
| EP-1325946-A2 | Coating composition for the protection of packaging and interconnecting boards | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2003-07-09 | — | — | EP | disclosed |
| US-6448427-B1 | REACTING AN ALKALI-METAL SALT OF (METH)ACRYLIC ACID WITH A HALOGEN SUBSTITUTED ORGANOSILICON COMPOUND IN THE PRESENCE OF A TERTIARY AMINE DIAZABICYCLO DERIVATIVE | DOW CORNING TORAY SILICONE CO., LTD. (JP) | 2002-09-10 | — | — | US | disclosed |
| EP-1234830-A2 | Method of preparing an organosilicon compound containing a methacryloxy functional group | Dow Corning Toray Silicone Co., Ltd. (JP) | 2002-08-28 | — | — | EP | disclosed |
| US-20020115878-A1 | METHOD OF PREPARING AN ORGANOSILICON COMPOUND CONTAINING A METHACRYLOXY FUNCTIONAL GROUP | DOW TORAY CO., LTD. (JP) | 2002-08-22 | — | — | US | disclosed |
| EP-0486279-B2 | Process for removing acidic impurities from alkoxysilanes | SHINETSU CHEMICAL CO (JP) | 1999-12-01 | — | — | EP | disclosed |
| US-5502096-A | POLYSILOXANES OR POLYETHERS FOR CURABLE RUBBER POLYMERS BOTH HAVING SILYL BLOCKING GROUPS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 1996-03-26 | — | — | US | disclosed |
| US-5247117-A | Neutralization with sterically hindered alcohols or amines, distillation | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 1993-09-21 | — | — | US | disclosed |
| EP-0486279-A1 | Process for removing acidic impurities from alkoxysilanes | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 1992-05-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028440-A1 | Curable Composition for Producing Transparent Orthodontic Attachments | SMCHD1, SMC2, SMC1A | TSHR 705/4885HPGD 4304/4885ALDH1A1 1413/4885 |
| US-20260139157-A1 | THERMAL-AND-UV-CURABLE (METH)ACRYLATE COMPOSITION | MAT1A, MAT2B, MAT2A | TSHR 2841/4885HPGD 2616/4885ALDH1A1 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.